Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Videos

Jamie Chaft, MD
Videos
The Case for Immunotherapy Alone for Patients With PD-L1-High NSCLC in the First-Line Setting
09/29/2023

Featuring Jamie Chaft, MD 

Featuring Jamie Chaft, MD 
At the Great Debates & Updates meeting in New York, Jamie Chaft, MD, debated in favor of using immunotherapy alone in the first-line setting for patients with high PD-L1 expression and non-small cell lung cancer.
At the Great Debates & Updates meeting in New York, Jamie Chaft, MD, debated in favor of using immunotherapy alone in the first-line setting for patients with high PD-L1 expression and non-small cell lung cancer.
At the Great Debates & Updates...
09/29/2023
Oncology

Advertisement

Misako Nagasaka, MD, PhD
Videos
The Case for Lorlatinib in ALK-Positive NSCLC
09/28/2023

Featuring Misako Nagasaka, MD, PhD

Featuring Misako Nagasaka, MD, PhD ...
At the Great Debates & Updates in Lung Cancer meeting, Misako Nagasaka, MD, PhD, debated in favor of lorlatinib over alectinib when considering treatment options for patients with ALK-positive non-small cell lung cancer (NSCLC).
At the Great Debates & Updates in Lung Cancer meeting, Misako Nagasaka, MD, PhD, debated in favor of lorlatinib over alectinib when considering treatment options for patients with ALK-positive non-small cell lung cancer (NSCLC).
At the Great Debates & Updates...
09/28/2023
Oncology
Corey Langer, MD
Videos
How to Handle Elderly Patients and Those With Performance Status 2 NSCLC
09/28/2023

Featuring Corey Langer, MD

Featuring Corey Langer, MD
At the Great Debates & Updates in Lung Cancer meeting Corey Langer, MD, discussed the therapeutic landscape for underserved patients with non-small cell lung cancer — elderly patients, and patients with ECOG performance status 2.
At the Great Debates & Updates in Lung Cancer meeting Corey Langer, MD, discussed the therapeutic landscape for underserved patients with non-small cell lung cancer — elderly patients, and patients with ECOG performance status 2.
At the Great Debates & Updates...
09/28/2023
Oncology
Aparna Parikh, MD, MGH Cancer Center
Videos
The Role of Circulating Tumor DNA in Colorectal Cancer
09/28/2023

Featuring Aparna Parikh, MD

Featuring Aparna Parikh, MD
At the Great Debates & Updates in Gastrointestinal Malignancies meeting, Aparna Parikh, MD, presented on the role circulating tumor DNA may have in the treatment of patients with colorectal cancer.
At the Great Debates & Updates in Gastrointestinal Malignancies meeting, Aparna Parikh, MD, presented on the role circulating tumor DNA may have in the treatment of patients with colorectal cancer.
At the Great Debates & Updates...
09/28/2023
Oncology

Advertisement

Patrick Forde, MD
Videos
The Case for Adjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
09/26/2023

Featuring Patrick Forde, MD

Featuring Patrick Forde, MD
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Patrick Forde, MD, debated in favor of adjuvant immunotherapy in resectable non-small cell lung cancer.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Patrick Forde, MD, debated in favor of adjuvant immunotherapy in resectable non-small cell lung cancer.
At the Great Debates & Updates...
09/26/2023
Oncology
Patrick Forde, MD
Videos
The Case for Chemoimmunotherapy for Patients With PD-L1-High Non-Small Cell Lung Cancer in the First-Line Setting
09/26/2023

Featuring Patrick Forde, MD

Featuring Patrick Forde, MD
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Patrick Forde, MD, Johns Hopkins, debated in favor of chemoimmunotherapy in PD-L1 high non-small cell lung cancer.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Patrick Forde, MD, Johns Hopkins, debated in favor of chemoimmunotherapy in PD-L1 high non-small cell lung cancer.
At the Great Debates & Updates...
09/26/2023
Oncology
Hossein Borghaei, DO, MS
Videos
Novel Checkpoint Inhibitor Combinations for Lung Cancer
09/26/2023

Featuring Hossein Borghaei, DO, MS

Featuring Hossein Borghaei, DO, MS ...
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Hossein Borghaei, DO, MS, discussed the development of novel combinations of checkpoint inhibitors to better treat patients with refractory lung cancers.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Hossein Borghaei, DO, MS, discussed the development of novel combinations of checkpoint inhibitors to better treat patients with refractory lung cancers.
At the Great Debates & Updates...
09/26/2023
Oncology

Advertisement

Charles B. Simone II, MD
Videos
The Case for Prophylactic Cranial Irradiation in Small-Cell Lung Cancer
09/26/2023

Featuring Charles B. Simone, MD

Featuring Charles B. Simone, MD ...
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Charles Simone, MD, debated in favor of prophylactic cranial irradiation when considering treatment options for patients with small-cell lung cancer.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Charles Simone, MD, debated in favor of prophylactic cranial irradiation when considering treatment options for patients with small-cell lung cancer.
At the Great Debates & Updates...
09/26/2023
Oncology
Lyudmila Bazhenova, MD
Videos
Management of BRAF-Mutated Non-Small Cell Lung Cancer
09/26/2023

Featuring Lyudmila Bazhenova, MD

Featuring Lyudmila Bazhenova, MD ...
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Lyudmila Bazhenova, MD, discussed developments and advances in the management of BRAF-mutated NSCLC.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Lyudmila Bazhenova, MD, discussed developments and advances in the management of BRAF-mutated NSCLC.
At the Great Debates & Updates...
09/26/2023
Oncology
Hossein Borghaei, DO, MS
Videos
The Case for Using Immunotherapy for Patients With Low or Negative PD-L1
09/26/2023

Featuring Hossein Borghaei, DO, MS

Featuring Hossein Borghaei, DO, MS ...
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Hossein Borghaei, DO, MS, debated in favor of using immunotherapy among patients with non-small lung cancer and PD-L1 expressions of
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Hossein Borghaei, DO, MS, debated in favor of using immunotherapy among patients with non-small lung cancer and PD-L1 expressions of
At the Great Debates & Updates...
09/26/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use